The EIB has awarded Estonian CDMO Icosagen €18 million, supporting the financing of a 1,600
m2 production facility.
The European Investment Bank has awarded Estonian CDMO Icosagen €18 million ($19 million),
supporting the financing of a 1,600 m2 production facility.
The €18 million will form part of a total of €40 million being invested into contract development and manufacturing organization (CDMO) Icosagen’s R&D capabilities and a clinical-scale good manufacturing practice (GMP) plant in Tartu, Estonia.
The 1,600 m2 facility is scheduled to be project-ready in Q1 2024 and will include a 400 m2
cleanroom equipped with single-use bioreactors up to 1,000 L in scale, supplied by MilliporeSigma.
Downstream equipment – also part of MilliporeSigma’s Mobius range – will be capable of
processing kg-amounts of product, suitable for Phase I and II clinical trials.
https://www.bioprocessintl.com/facilities-capacity/icosagen-eib-loan-to-support-cdmo-s-mammalian-plant-buildout
Don't miss out on the excitement! Reserve your spot at one of our upcoming events:
SCALE UP WITH WOLVES AND EUROPEAN CVC AWARDS
26 March 2024, Spielfeld Digital Hub, Germany + online
WOLVES SUMMIT CEE
8-9 May 2024, Copernicus Science Centre, Warsaw, Poland + online